NEWS

The National Institutes of Health is funding "High-throughput kinetic system for small-molecule drug discovery." Capienda Biotech wins an NIH Grant ($329K) to complete Research & Development of the novel laboratory instrument and assay chemistry. The project advances upon R&D funded by a $256K National Science Foundation grant.

 
Drug discovery and Lead Optimization typically rely on IC50 measurements. Equilibrium results are important, but kinetic insight is needed to assess mechanism and predict performance. What if Med Chemists and AI/ML could be guided by just as many binding kinetic results as their traditional IC50/Kd results? 

Capienda aims to provide Medicinal Chemists and AI Drug Discovery enough kinetic data to improve drug discovery and lead optimization, which may lead to higher chances for new medicines to succeed in the clinic.

https://reporter.nih.gov/search/MB0qVpjDhUiKEQq1m9LH4A/project-details/11069377

Any opinions or recommendations expressed are those of Capienda Biotech and do not necessarily reflect the views of the National Institutes of Health or the National Science Foundation. 

CAPIENDA BIOTECH is awarded a Small Business Innovation Research (SBIR) Phase I grant by the National Science Foundation (NSF) to develop a high-throughput kinetics system for small molecule drug discovery.

Project impact: help Medicinal Chemists find drug candidates that can stick persistently to the correct target and work better in patients. By coming off the target prematurely, a drug stops working and may be cleared rapidly from the body. Current state-of-the-art technologies find weak binders and are plagued by other limitations. The system proposed herein tests large numbers of compounds at high throughput during drug discovery and lead optimization, replacing current systems with low throughput.  

The proposed project will solve an unmet analytical need in drug discovery and lead optimization by providing kinetic results at high throughput to refine drug designs. The proposed novel instrument and assay chemistry system measures how long chemical compounds stay on target.

https://nsf.gov/awardsearch/showAward?AWD_ID=2127159

CAPIENDA BIOTECH advances to the Quarterfinals of the San Diego Angel Conference. Dr. Mark Bernard will present the business opportunity and biotechnology innovation to the SDAC on January 28, 2021.  Competition is for $200,000 in funding.

San Diego Angel Conference Investors Select 30 Quarter Finalists From Record 124 Applications

https://www.thesdangels.com/san-diego-angel-conference-investors-select-30-quarter-finalists-from-record-124-applications/

CAPIENDA BIOTECH is selected as a top 15 entrant for the 2020 BI Innovation Prize being awarded by Boehringer Ingelheim GmbH and the Boehringer Ingelheim Venture Fund. Dr. Mark Bernard presents the business opportunity and biotechnology innovation to the SDAC on February 27, 2020. The Golden Ticket is a $75,000 value for BioLabs shared laboratory space in San Diego for one year.

https://innovation.ucsd.edu/events/boehringer-ingelheim-innovation-prize/

CAPIENDA BIOTECH advances to the Quarterfinals of the San Diego Angel Conference. Dr. Mark Bernard will present the business opportunity and biotechnology innovation to the SDAC on February 5, 2020.  Competition is for $200,000 in funding.

http://www.sdbj.com/news/2020/feb/20/quarter-finalists-named-san-diego-angel-conference

https://www.thesdangels.com/news-release-2020-san-diego-angel-conference-quarterfinalists-announced/

CAPIENDA BIOTECH completed the National Science Foundation Innovation Corps Program at Tech Launch Arizona (TLA) and the University of Arizona. Capienda was a member of Cohort #9 at TLA. 

The goal of the NSF Innovation Corps (I-Corps) Program is to reduce the time and risk associated with translating promising ideas and technologies from the laboratory to the marketplace. The I-Corps Program utilizes experiential learning of customer and industry discovery, coupled with first-hand investigation of industrial processes, to quickly assess the translational potential of inventions. The I-Corps Program is designed to support the commercialization of so-called "deep technologies,” or those revolving around fundamental discoveries in science and engineering. The I-Corps program addresses the skill and knowledge gap associated with the transformation of basic research into deep technology ventures (DTVs).